| Name | Title | Contact Details |
|---|
We are a clinical-stage biopharmaceutical company focused on changing the lives of patients living with nonalcoholic steatohepatitis (NASH) and other liver and metabolic disorders. Our teams in the US and Israel are developing highly differentiated medicines that address unmet medical needs based on robust research. Our lead product candidate, BIO89-100, is a novel long-acting glycopegylated fibroblast growth factor 21 (FGF21) analogue.
Cerecor is building a global biopharmaceutical enterprise with a near-term pipeline of six clinical programs. All of our pipeline products have unique and novel mechanisms of action with the potential to be first-in-class compounds.
BioElectronics Corporation is a Frederick, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Bio Essence Corp is a Richmond, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Reichert Analytical Instruments is a Depew, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.